X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (964) 964
Publication (76) 76
Book Review (31) 31
Book Chapter (11) 11
Book / eBook (2) 2
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rheumatoid arthritis (690) 690
rheumatology (602) 602
dmards (569) 569
humans (501) 501
index medicus (482) 482
antirheumatic agents - therapeutic use (348) 348
arthritis, rheumatoid - drug therapy (337) 337
methotrexate (293) 293
female (276) 276
male (269) 269
middle aged (249) 249
treatment outcome (212) 212
double-blind (196) 196
adult (185) 185
1506 (175) 175
aged (166) 166
arthritis (164) 164
dmard (152) 152
treatment (144) 144
care and treatment (143) 143
patients (136) 136
therapy (134) 134
drug therapy, combination (133) 133
antirheumatic agents (131) 131
etanercept (131) 131
drug therapy (119) 119
modifying antirheumatic drugs (116) 116
rheumatoid factor (116) 116
infliximab (115) 115
methotrexate - therapeutic use (109) 109
tumor necrosis factor-tnf (107) 107
antirheumatic agents - adverse effects (105) 105
rheumatoid-arthritis (103) 103
tumor necrosis factor-alpha - antagonists & inhibitors (102) 102
anti-tnf (96) 96
severity of illness index (94) 94
safety (92) 92
studies (92) 92
efficacy (91) 91
biologics (87) 87
dosage and administration (85) 85
remission (85) 85
antirheumatic agents - administration & dosage (83) 83
biological products - therapeutic use (83) 83
clinical trials (82) 82
medicine & public health (82) 82
adalimumab (79) 79
clinical and epidemiological research (79) 79
risk factors (79) 79
musculoskeletal diseases (78) 78
disease (75) 75
drug dosages (73) 73
analysis (72) 72
usage (71) 71
recommendations (70) 70
tnf inhibitors (69) 69
disease-activity (68) 68
psoriatic arthritis (63) 63
skin and connective tissue diseases (61) 61
epidemiology (60) 60
placebo-controlled trial (60) 60
inadequate response (59) 59
research (59) 59
inflammation (58) 58
combination therapy (57) 57
clinical medicine (56) 56
combination (55) 55
remission induction (55) 55
tocilizumab (55) 55
double-blind method (53) 53
drugs (53) 53
immunology (53) 53
arthritis, rheumatoid - diagnosis (51) 51
biological products (51) 51
abridged index medicus (50) 50
american-college (49) 49
cytokines (49) 49
health aspects (49) 49
antibodies, monoclonal, humanized - therapeutic use (47) 47
antibodies, monoclonal - therapeutic use (46) 46
corticosteroids (46) 46
disease activity (46) 46
management (46) 46
health risk assessment (45) 45
multicenter (45) 45
pharmacology & pharmacy (45) 45
disease progression (44) 44
monoclonal-antibody (44) 44
abatacept (43) 43
early rheumatoid arthritis (43) 43
eular recommendations (43) 43
internal medicine (43) 43
infections (42) 42
biologic dmards (41) 41
medicine, general & internal (41) 41
prospective studies (40) 40
quality of life (40) 40
rituximab (40) 40
biologic agents (39) 39
arthritis, rheumatoid - immunology (38) 38
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (913) 913
German (31) 31
Japanese (10) 10
French (7) 7
Spanish (6) 6
Portuguese (3) 3
Korean (2) 2
Chinese (1) 1
Czech (1) 1
Italian (1) 1
Polish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue 6, pp. 905 - 910
ObjectivesTo compare the incidence of serious infection (SI) across biologic drugs used to treat rheumatoid arthritis (RA) using data from the British Society... 
dmards (biologic) | infections | epidemiology | rheumatoid arthritis | BACTERIAL-INFECTIONS | ADALIMUMAB | EFFICACY | SAFETY | MONOCLONAL-ANTIBODY | RHEUMATOLOGY | FACTOR-ALPHA | TOCILIZUMAB | TUMOR-NECROSIS-FACTOR | INCREASED RISK | DOUBLE-BLIND | Follow-Up Studies | Humans | Middle Aged | Male | Infliximab - therapeutic use | Opportunistic Infections - chemically induced | Incidence | Certolizumab Pegol - adverse effects | Infliximab - adverse effects | Arthritis, Rheumatoid - drug therapy | Sensitivity and Specificity | Antirheumatic Agents - adverse effects | Adult | Biological Products - adverse effects | Female | Registries | Certolizumab Pegol - therapeutic use | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Antibodies, Monoclonal, Humanized - adverse effects | Etanercept - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Opportunistic Infections - epidemiology | Risk Factors | Arthritis, Rheumatoid - epidemiology | Aged | United Kingdom - epidemiology | Etanercept - therapeutic use | Drugs | Bacterial infections | Intravenous administration | Biological products | Mortality | Rheumatology | Infections | Tumor necrosis factor-α | Patients | Meta-analysis | Polypharmacy | Etanercept | Antibiotics | Rheumatoid arthritis | Questionnaires | Monoclonal antibodies | TNF inhibitors | Sepsis | Tumor necrosis factor-TNF
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 03/2014, Volume 73, Issue 3, pp. 492 - 509
Journal Article
Journal Article
Rheumatology (United Kingdom), ISSN 1462-0324, 2015, Volume 54, Issue 12, pp. 2156 - 2165
Journal Article
Journal Article